

Arno de Wilde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4076360/publications.pdf>

Version: 2024-02-01

26
papers

895
citations

623734

14
h-index

839539

18
g-index

28
all docs

28
docs citations

28
times ranked

1628
citing authors

#	ARTICLE	IF	CITATIONS
1	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
2	The Alzheimer's disease drug development landscape. Alzheimer's Research and Therapy, 2021, 13, 186.	6.2	49
3	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. Alzheimer's and Dementia, 2021, 17, .	0.8	0
4	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
5	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Frontiers in Neurology, 2020, 11, 592302.	2.4	23
6	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
7	Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537.	2.4	8
8	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.1	51
9	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's and Dementia, 2019, 15, 1458-1467.	0.8	18
10	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	6.2	40
11	PET and CSF amyloid- β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
12	Stress in Patients With (Un)ruptured Intracranial Aneurysms vs Population-Based Controls. Neurosurgery, 2019, 84, 1065-1071.	1.1	11
13	LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	0.8	0
14	TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS IN THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P1058.	0.8	0
15	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, 72.	6.2	34
16	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurology, 2018, 75, 1062.	9.0	102
17	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	2.4	57
18	Genetic variants associated with type 2 diabetes and adiposity and risk of intracranial and abdominal aortic aneurysms. European Journal of Human Genetics, 2017, 25, 758-762.	2.8	13

#	ARTICLE	IF	CITATIONS
19	[ICâ€™05]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€™ ² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.8	1
20	[P2â€™207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€™ ² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.8	0
21	[Dâ€™02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.8	0
22	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
23	ICâ€™11: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.8	0
24	Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biology, 2015, 13, e1002273.	5.6	240
25	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0
26	Long-term outcome after aneurysmal subarachnoid hemorrhageâ€™ risks of vascular events, death from cancer and all-cause death. Journal of Neurology, 2014, 261, 309-315.	3.6	22